SEC Contract Filing

Filing Date: 2025-03-13

Document Content:
<DOCUMENT>
<TYPE>EX-10.105
<SEQUENCE>4
<FILENAME>ex10105akebiakreossecondam.htm
<DESCRIPTION>EX-10.105
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4a68035e28874268a01018e766bacfa7_1"></div><div style="min-height:116.64pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.105</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Execution Version</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Double asterisks denote omissions.</font></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">SECOND AMENDMENT TO AGREEMENT FOR THE PROVISION OF A LOAN FACILITY</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">This </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">SECOND AMENDMENT TO AGREEMENT FOR THE PROVISION OF A LOAN FACILITY </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Amendment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8221;), dated as of February 3, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Amendment Effective Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8221;), is made by and between </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">KREOS CAPITAL VII (UK) LIMITED</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">, a company incorporated in England and Wales under registration number 13611522 whose registered office is at 8 Sackville Street, London, WS1 3DG, as a Lender (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Lender</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8221; and &#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Lender Representative</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#34;, which expression shall include its permitted successors and permitted assigns), and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">AKEBIA THERAPEUTICS, INC.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Borrower</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8221; and &#34;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Borrower Representative</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#34;), and amends that certain AGREEMENT FOR THE PROVISION OF A LOAN FACILITY dated as of January 29, 2024 (as amended by that certain First Amendment to Agreement for the Provision of a Loan Facility, dated as of July 10, 2024, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Existing Loan Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8221;) by and between the Lender Representative and the Borrower Representative and the other parties thereto from time to time. The Existing Loan Agreement as amended by this Amendment is hereinafter referred to as the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Loan Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8221;. Capitalized terms used in this Amendment without definition shall have the meanings ascribed to such terms in the Loan Agreement.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">WHEREAS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">, the Borrower Representative and the Lender Representative are party to the Existing Loan Agreeme